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Thymic stromal lymphopoietin blocks early stages
of breast carcinogenesis
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Melissa A. Meyers,4 David G. DeNardo,4 and Wayne M. Yokoyama3,5
Center for Cancer Immunology and Cutaneous Biology Research Center, Department of Dermatology and MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School,

1

Boston, Massachusetts, USA. 2Division of Dermatology, 3Division of Rheumatology, 4Division of Oncology, Department of Medicine, and 5Howard Hughes Medical Institute,
Washington University School of Medicine, Saint Louis, Missouri, USA.

Advances in the field of cancer immunology, including studies on tumor-infiltrating CD8+ cytotoxic T lymphocytes (CTLs),
have led to new immunotherapeutics with proven efficacy against late-stage cancers. However, the antitumor potential
of the immune system in targeting early-stage cancers remains uncertain. Here, we demonstrated that both genetic and
chemical induction of thymic stromal lymphopoietin (TSLP) at a distant site leads to robust antitumor immunity against
spontaneous breast carcinogenesis in mice. Breast tumors exposed to high circulating levels of TSLP were arrested at an
early adenoma-like stage and were prevented from advancing to late carcinoma and metastasis. Additionally, CD4+ Th2
cells mediated the antitumor effects of TSLP, challenging the notion that Th2 cells only promote cancer. We also discovered
that TSLP is expressed by the breast tumor cells themselves and acts to block breast cancer promotion. Moreover, TSLPinduced immunity also blocked early stages of pancreatic cancer development. Together, our findings demonstrate that
TSLP potently induces immunity directed against early stages of breast cancer development without causing inflammation
in the normal breast tissue. Moreover, our results highlight a previously unappreciated function of the immune system in
controlling the early development of cancer and establish a fundamental role for TSLP and Th2 cells in tumor immunity
against early-stage cancers.

Introduction

Studies of the immune response to late-stage cancers including the role of tumor-infiltrating CD8+ cytotoxic T lymphocytes
(CTLs) in attacking cancer cells have led to promising new cancer
immunotherapeutics with proven efficacy against melanoma and
other metastatic cancers (1). However, the efficacy of immunotherapeutic approaches for the treatment of early-stage cancers is
uncertain (2). This is particularly relevant to carcinomas, because
these cancers frequently lack a significant antitumor immune
infiltrate, especially during the early in situ phases of their development (3). The current cancer immunotherapies like immune
checkpoint blockade, which rely on a preexisting CTL infiltrate in
the tumor for their effects, have relatively low efficiency against
the early nonimmunogenic carcinomas (2, 4). In order to expand
the potential of cancer immunotherapy, it is essential to find pathways that lead to immune system activation against early phases
of cancer development. Therefore, devising a mechanism to activate the immune system against early-stage cancers has clear therapeutic implications, both by directly blocking cancer promotion
and potentiating the effects of the available cancer immunotherapeutics against the late disease.
To substantiate the possibility of immunotherapy for early
cancers, we have studied thymic stromal lymphopoietin (TSLP),
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which is emerging as an important cytokine in cancer immunology (5). TSLP is an epithelium-derived cytokine that is a master
regulator of allergic inflammation at barrier organs like the skin
and lungs (6). We and others have previously demonstrated that
epidermis-derived TSLP creates robust antitumor immunity in the
skin by activating CD4+ T cells against early stages of skin cancer
development (7–9). Interestingly, TSLP is expressed by mouse
and human mammary gland epithelia and breast cancer cells (10),
which raises the possibility that this cytokine may also play a role
during the early stages of breast cancer development. Importantly,
skin-derived TSLP, which can be induced by the FDA-approved
topical medication calcipotriol (11, 12), can reach high systemic levels and activate the immune response in internal organs (13, 14).
In addition, epidemiological data suggest that individuals with a
history of allergic diseases like atopic dermatitis and asthma have a
reduced risk of developing breast cancer (15–17), which may potentially be explained by elevated circulating TSLP levels in these individuals (18). Thus, an intriguing possibility with clear therapeutic
implications is that systemic TSLP can induce antitumor immunity
against early stages of breast cancer development.
To test the hypothesis that TSLP is active in preventing breast
cancer, we studied the impact of TSLP expressed in the skin on
breast tumor promotion in a murine model of spontaneous breast
carcinogenesis. We demonstrate that TSLP blocks breast cancer
development through activation of Th2 cells that heavily infiltrate
the breast tumors. Interestingly, we discovered that TSLP released
by breast tumor cells themselves functions to prevent breast
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tumor promotion. In addition, we show that induction of TSLP
mounts a similar antitumor immune response against pancreatic
cancer development. Collectively, these data establish a fundamental role for immune activation in combating the early stages
of carcinogenesis and identify the mechanism for TSLP-mediated
antitumor immunity against breast cancer.

Results

TSLP overexpression in the skin leads to T cell accumulation at the
site of developing breast cancer. In order to determine the impact of
systemic TSLP on the early stages of breast cancer development,
we studied MMTV-polyoma middle T (PyMttg) mice, a well-established spontaneous model of breast cancer that mimics luminal
breast cancer in humans (19). We crossed this breast cancer–prone
strain with mice that overexpress TSLP in their skin (K14-TSLPtg)
(20). K14-TSLPtg animals develop allergic inflammation in their
skin, which mimics atopic dermatitis in humans (13). To determine the site of TSLP expression in the animals relevant to our
current studies, we assessed Tslp mRNA expression in the skin and
breast glands of WT, K14-TSLPtg, and K14-TSLPtg Tslpr–/– mice,
which lack TSLP-induced allergic inflammation. We detected
Tslp transgene expression in the skin, but not in the breast glands
(Supplemental Figure 1, A and B; supplemental material available
online with this article; doi:10.1172/JCI83724DS1). Importantly,
we demonstrated that Tslp overexpression in the skin led to high
serum TSLP levels in K14-TSLPtg and K14-TSLPtg PyMttg animals
(Supplemental Figure 1C). Therefore, K14-TSLPtg PyMttg animals could be used to investigate the impact of systemic TSLP on
breast cancer development.
Analysis of the inflammatory phenotypes in K14-TSLPtg PyMttg
animals demonstrated the development of atopic dermatitis in the
skin at 10 weeks of age, which was highlighted by epidermal thickening and dermal inflammatory infiltrate including CD4+ T cells
(Figure 1A and Supplemental Figure 2). We also observed an accumulation of mast cells in the dermis of K14-TSLPtg and K14-TSLPtg
PyMttg animals (Figure 1A; P < 0.05, Student’s t test) (20). Similar
to K14-TSLPtg mice (13, 14), K14-TSLPtg PyMttg animals underwent
atopic march and developed allergic inflammation at other barrier
sites, as shown by the accumulation of T cell–rich inflammatory
infiltrates around the lung airways (Figure 1B). Interestingly and
in stark contrast to K14-TSLPtg mice lacking inflammation in their
breast, 10-week-old K14-TSLPtg PyMttg mice showed a significant
accumulation of CD4+ T cells surrounding their dilated mammary
glands (Figure 1C). No CD4+ T cell infiltrate was detectable in early
breast tumors of 10-week-old PyMttg animals (Figure 1C). Notably, the early breast tumors developing in 10-week-old K14-TSLPtg
PyMttg animals mostly presented as dilated mammary ducts and
lacked the epithelial hyperplasia seen in PyMttg breast ductal walls
(Figure 1C). These findings suggest that TSLP stimulates a robust
immune response in the breast primarily in the context of a developing tumor, which prevents the tumor from progressing into fully
formed carcinoma at the primary site.
TSLP induction blocks breast carcinogenesis in the adenoma-like
stage. To determine the effects of systemic TSLP on breast cancer
outcomes, we monitored spontaneous breast cancer development in K14-TSLPtg PyMttg mice with allergic inflammation and
compared it with their PyMttg littermates over time (Figure 2).

Research article

We found that K14-TSLPtg PyMttg mice had a significantly longer
latency to breast tumor development (Figure 2A; P < 0.001, logrank test). In addition, the number of palpable breast tumors in
each K14-TSLPtg PyMttg animal was significantly reduced compared with that observed in PyMttg mice (Figure 2B; P < 0.05, starting at 10 weeks of age, Student’s t test). Most notably, the lifespan
of K14-TSLPtg PyMttg animals was not affected by their breast cancer burden after 150 days, a point at which all PyMttg mice had succumbed to their cancer (Figure 2C; P < 0.001, log-rank test). This
stark contrast in survival rates between the 2 groups was due to the
significantly smaller number of breast tumors in the K14-TSLPtg
PyMttg mice, and these tumors remained small adenoma-like precancers that lacked metastatic potential (Figure 2D and Supplemental Figure 3). Thus, the K14-TSLPtg PyMttg mice were greatly
protected from breast cancer.
Antitumor effect of TSLP is associated with a Th2-dominant
immune response at the site of developing breast tumors. To examine the possibility that TSLP-mediated breast cancer suppression
was caused by underdeveloped mammary glands or by a lack of
cancer initiation in K14-TSLPtg PyMttg mice, we stained the whole
mount of mammary glands and tumors from adult WT, K14TSLPtg, PyMttg, and K14-TSLPtg PyMttg female mice with carmine
stain to visualize the extent of mammary gland branching and the
status of the tumors in the PyMt transgene–positive cohorts (21).
Importantly, TSLP overexpression from the skin had no impact on
the development of female mammary glands and their branching
after puberty (Figure 3A). In addition, the presence of multiple
dilated foci along the mammary ducts in K14-TSLPtg PyMttg breast
(Figure 3A) clearly demonstrates that TSLP does not affect the
initiation phase of breast carcinogenesis, but instead effectively
blocks its promotion.
The suppressive effects of TSLP in blocking breast cancer
promotion could possibly be mediated through the activation of
antitumor immunity in the breast. To investigate this possibility,
we characterized the immune environment in breast glands and
tumors from age-matched WT, K14-TSLPtg, PyMttg, and K14TSLPtg PyMttg female mice at the time when PyMttg mice had
developed metastatic breast cancers (Figure 3). WT and K14TSLPtg breast glands had no immune infiltrate around the mammary ducts (Figure 3B), similar to that seen at earlier time points
(Figure 1). At the later stage, PyMttg breast cancers were composed
of densely packed collections of breast cancer cells with scattered
T cells within them; however, K14-TSLPtg PyMttg breast tumors
contained a dense CD4+ T cell infiltrate in close proximity to
dilated mammary ducts in the tumor (Figure 3B). Quantification
of the tumor-infiltrating T cells demonstrated that the majority of
tumor-infiltrating T cells in PyMttg breast tumors were CD8+ CTLs,
but CD4+ T cells were the dominant T cell type in K14-TSLPtg
PyMttg breast tumors (Figure 3C). The accumulation of CD4+ T
cells in K14-TSLPtg PyMttg breast tumors occurred in the presence
of high serum TSLP levels during the development of breast cancer in these animals (Figure 3, C and D). Importantly, CD4+ T cells
infiltrating the K14-TSLPtg PyMttg breast tumors did not express
cytotoxic factors like granzyme B or FasL; however, their accumulation in K14-TSLPtg PyMttg breast tumors was accompanied by a
significant reduction in the expression of the tumor-promoting
factors IL-6 (22) and IL-8 (23) within the tumor microenvironment
jci.org   Volume 126   Number 4   April 2016
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Figure 1. TSLP overexpression in the skin leads to allergic inflammation in barrier organs and induces a CD4+ T cell–mediated immune response to the
developing breast tumors. (A) TSLP expression in the skin causes atopic dermatitis–like inflammation. Representative images of H&E and toluidine blue
staining (highlighting mast cells in purple) of skin from 10-week-old WT, K14-TSLPtg, PyMttg, and K14-TSLPtg PyMttg mice are shown. The average number
of mast cells in 10 random high-power fields (hpf) is shown as a bar graph at the left edge of the images (*P < 0.05 compared with WT, Student’s t test).
(B) Elevated systemic TSLP levels caused inflammation in the lungs. Representative images of H&E and CD3 staining (marking T cells) of lungs from
10-week-old WT, K14-TSLPtg, PyMttg, and K14-TSLPtg PyMttg mice. Arrows point to the foci of inflammation around lung airways. Higher-magnification representative images of CD3-stained lung airways are shown. Bar graphs at the left edge of the CD3-stained images show the average number of lymphocyte
aggregate foci per lung section in 10 random lungs from each cohort (*P < 0.05 compared with WT, Student’s t test). (C) TSLP induction led to accumulation of CD4+ T cells at the site of breast cancer development and to its arrest. Representative images of H&E, CD3 immunohistochemical, CD4, CD3, and
cytokeratin (CK) immunofluorescence staining of breast glands and early tumors from 10-week-old WT, K14-TSLPtg, PyMttg, and K14-TSLPtg PyMttg mice.
The average number of tumor-infiltrating CD4+ T cells in 10 random hpf is shown as a bar graph at the left edge of the immunofluorescence images
(*P < 0.05 compared with WT, Student’s t test). Data were reproduced in 3 independent experiments. Scale bars: 100 μm.

(Supplemental Figure 4). Thus, systemic TSLP induction blocks
breast cancer promotion and is associated with a large number of
CD4+ T cells infiltrating the developing breast cancer.
Detailed analysis of the immune cells in tumor-draining
lymph nodes of PyMttg and K14-TSLPtg PyMttg animals showed a
1460
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marked increase in CD4+ T and CD8+ T lymphocytes with effector and memory phenotypes in K14-TSLPtg PyMttg mice compared
with that seen in PyMttg mice (Supplemental Figure 5). Interestingly, only CD4+ T cells in K14-TSLPtg PyMttg lymph nodes showed
increased expression of an activation marker, PD-1 (Supplemental

Downloaded from http://www.jci.org on May 1, 2016. http://dx.doi.org/10.1172/JCI83724

The Journal of Clinical Investigation  

Research article

Figure 2. TSLP blocks breast cancer development. (A–C) K14-TSLPtg PyMttg female mice were protected from breast cancer compared with their PyMttg
counterparts. Graphs show (A) the time to tumor onset, (B) the average number of breast tumors per mouse, and (C) the animals’ rate of survival (n ≥14 in
each group; *P < 0.05 starting at week 10, Student’s t test; **P < 0.001, log-rank test). (D) K14-TSLPtg PyMttg female mice had atopic dermatitis–like skin
rashes but smaller adenomatous breast tumors and no lung metastasis compared with PyMttg mice. Representative images of H&E-stained breast cancer
and lung tissue from K14-TSLPtg PyMttg and PyMttg female mice. Scale bars: 1 cm (mouse), 1 mm (histology).

Figure 5). CD4+ T cells stained for the GATA3 and FOXP3 transcription factors identified the expanded population of CD4+
T cells in K14-TSLPtg PyMttg lymph nodes as being GATA3+ Th2
cells, while FOXP3+ Tregs were the dominant CD4+ T cell type in
the PyMttg immune microenvironment (Supplemental Figure 5).
Consistent with these findings, the expression of type 2 cytokines
like Il4 was significantly upregulated, whereas expression of type 1
cytokines such as Ifng and Tnf was significantly downregulated in
K14-TSLPtg PyMttg lymph nodes compared with that detected in
PyMttg lymph nodes (Figure 4A; P < 0.05, Student’s t test). TSLP
induction did not induce the expression of Il33, another epitheliumderived cytokine implicated in allergic inflammation (Figure 4A,
Supplemental Figure 6, and ref. 24). Importantly, immunophenotyping of the tumor-infiltrating T cells identified the majority of
these cells as CD4+ Th2 effector cells in K14-TSLPtg PyMttg breast
tumors, because the CD4+ T cells expressed GATA3 and lacked
T-bet or FOXP3 expression (Figure 4B). Despite the significant
Th2 cell infiltration into the K14-TSLPtg PyMttg breast tumors,
systemic TSLP did not result in the accumulation of mast cells
or basophils within the K14-TSLPtg PyMttg tumors (Supplemental
Figure 7). Finally, MHCII (I-Ab) staining of breast tumors from
K14-TSLPtg PyMttg mice generated on a pure C57BL/6 background
(H2b) showed the presence of MHC class II+ antigen-presenting
cells (APCs) in close contact with breast tumor cells and T cells
within K14-TSLPtg PyMttg breast tumors (Supplemental Figure 8).
CD11b+CD11c+ conventional DCs constituted the majority of the
MHC class II+ APCs in the breast tumors (Supplemental Figure 9

and refs. 25, 26). These findings firmly establish Th2 cells as the
dominant adaptive immune cells associated with TSLP-induced
antitumor immunity in the breast.
T cells mediate TSLP-induced antitumor immunity in the breast.
To determine whether T cells are required for TSLP-mediated
antitumor immunity in the breast, we performed weekly Ab-based
CD4+ and CD8+ T cell depletion in PyMttg and K14-TSLPtg PyMttg
animals starting in their second week of life, before the animals
reached puberty (Figure 5). Injection of animals with anti-CD4
and anti-CD8 Abs for up to 15 weeks led to complete depletion of
CD4+ and CD8+ T cells in the circulation (Supplemental Figure
10). Interestingly, there was complete resolution of skin inflammation in the K14-TSLPtg PyMttg animals, as shown by the normalization of hair coat, epidermal thickness, cellular density, and
mast cell counts in the dermis (Figure 5A and Supplemental Figure 10). Although depletion of T cells did not affect the kinetics
of breast cancer development in PyMttg animals (27), sustained T
cell depletion resulted in a clear loss of breast cancer resistance
in K14-TSLPtg PyMttg animals (Figure 5). K14-TSLPtg PyMttg animals treated with anti-CD4 and anti-CD8 Abs developed multiple invasive breast cancers with tumor latency similar to that in
PyMttg mice. Moreover, there were tumor metastases to the lungs
and survival was compromised (Figure 5, B–D, and Supplemental
Figure 11). To test whether CD4+ Th2 cells specifically mediated
the antitumor effects of TSLP in the K14-TSLPtg PyMttg breast,
we attempted to deplete only CD4+ or CD8+ T cells in K14-TSLPtg
PyMttg animals following the same protocol as above. Although
jci.org   Volume 126   Number 4   April 2016
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Figure 3. TSLP-induced breast cancer suppression is associated with accumulation of CD4+ T cells around the arrested breast tumor foci. (A) Breast
gland development in K14-TSLPtg PyMttg female mice was intact, but the breast cancer promotion phase was inhibited in these animals. Representative
images of carmine-stained (mammary ducts in red) breast glands and tumors from age-matched WT, K14-TSLPtg, PyMttg, and K14-TSLPtg PyMttg female
mice when PyMttg animals had developed palpable tumors. (B) Endpoint histological analysis revealed CD4+ T cell infiltrate surrounding dilated mammary ducts in K14-TSLPtg PyMttg female mice. Representative images show H&E, CD4/CD3/CK, and CD8/CD3/CK immunofluorecence staining of adjacent
sections of breast glands and tumors. Note that the tissues were from age-matched WT, K14-TSLPtg, PyMttg, and K14-TSLPtg PyMttg female mice when the
PyMttg animals had developed terminal metastatic breast cancers. (C) The majority of T cells in K14-TSLPtg PyMttg tumors were CD4+ T cells. Bar graphs
show the average number of tumor-infiltrating CD4+ and CD8+ T cells in 10 random hpf within the glands and tumors of WT, K14-TSLPtg, PyMttg, and
K14-TSLPtg PyMttg mice (*P < 0.05 compared with PyMttg, Student’s t test). (D) At the terminal stage of cancer in PyMttg mice, circulating TSLP levels rose
in PyMttg mice, but remained significantly higher in K14-TSLPtg and K14-TSLPtg PyMttg animals. Bar graph shows the serum TSLP levels in WT, K14-TSLPtg,
PyMttg, and K14-TSLPtg PyMttg female mice when the PyMttg animals had reached the metastatic breast cancer endpoint (n = 4 per group; *P < 0.05 compared with WT, Student’s t test). Data were reproduced in 3 independent experiments. Scale bars: 100 μm.

anti-CD8 Ab depletion alone led to an effective depletion of CD8+
T cells in K14-TSLPtg PyMttg blood, anti-CD4 Ab alone failed to
deplete CD4+ T cells, probably due to the TSLP stimulatory pressure on these cells (Supplemental Figure 12). Notably, and despite
the effective CD8+ T cell depletion, anti-CD8 Abs failed to alter the
allergic skin inflammation in the K14-TSLPtg PyMttg animals (Supplemental Figure 12, A and B). These findings demonstrate that
T cells play an essential role in mediating the antitumor immune
response mounted by TSLP in the breast and that CD4+ Th2 cells
are the likely T cell type required for this effect.
TSLP-stimulated Th2 cells are responsible for blocking breast
cancer promotion. We established the tumor-protective effects of
systemic TSLP against breast cancer using mice on a tumor-prone
FVB genetic background. In order to show similar effects in a different genetic background and provide the foundation for a more
detailed study of the role of CD4+ T cells in TSLP-mediated tumor
immunity, we studied K14-TSLPtg PyMttg and K14-TSLPtg PyMttg
Tslpr–/– animals generated on a pure C57BL/6 genetic background
(Supplemental Figure 13). Similar to the corresponding mice on the
1462
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FVB genetic background, K14-TSLPtg PyMttg mice on the C57BL/6
genetic background were resistant to breast cancer development,
and this resistance was completely reversed in K14-TSLPtg PyMttg
Tslpr–/– mice, which were prone to developing breast cancer to
a degree similar to that seen in PyMttg animals (Supplemental
Figure 13). To establish an experimental system that allowed for
a predictable tumor promotion time frame and controlled outcome measurements, we orthotopically implanted primary breast
tumor cells from PyMttg mice into the inguinal mammary fat
pads of WT and K14-TSLPtg recipients (Supplemental Figure 14).
Breast tumors grew significantly larger in WT animals compared
with that observed in their K14-TSLPtg counterparts, in which the
tumors were mostly arrested as small nodules that had dilated
breast ducts within them (Supplemental Figure 14; P < 0.05, Student’s t test). This result confirms that TSLP blocks the promotion
of an implanted primary breast tumor, which is identical to its
effects on a spontaneously forming breast tumor.
Next, we investigated the role of CD4+ T cells in TSLP-mediated immunity against breast cancer (Figure 6A). Primary breast
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Figure 4. TSLP induces the accumulation of CD4+ T cells and their polarization to Th2 cells in breast tumors and their draining lymph nodes. (A) Cyto
kine profiling of the tumor-draining lymph nodes revealed that the Th2-polarized cytokine milieu dominated in K14-TSLPtg PyMttg animals. Bar graphs
show the relative mRNA expression of several Th1- and Th2-related cytokines versus Gapdh in K14-TSLPtg PyMttg tumor–draining lymph nodes compared
with PyMttg tumor–draining lymph nodes (n = 4 per group; *P < 0.05 compared with PyMttg, Student’s t test). (B) Th2 cells formed the dominant type
of T cells infiltrating the K14-TSLPtg PyMttg breast tumors. Representative flow cytometric plots show the percentage of CD4+ and CD8+ T cells in PyMttg
and K14-TSLPtg PyMttg breast tumors. T-bet, GATA3, and FOXP3 transcription factor staining delineated the characteristics of the tumor-infiltrating CD4+
T cells in PyMttg and K14-TSLPtg PyMttg animals. Flow cytometric data were reproduced in 6 independent experiments. Data were collected when PyMttg
animals had reached the metastatic breast cancer endpoint. Numbers in the flow cytometric plots represent the percentage of the plotted cell population.
Bar graph demonstrates the percentage of Th1 and Th2 cells and Tregs within the PyMttg and K14-TSLPtg PyMttg breast tumors (n ≥4 per group; *P < 0.05
compared with PyMttg, Student’s t test).

tumors were isolated from PyMttg Tslpr–/– animals, which lack the
TSLP receptor on all their cells, including the immune cells that
might have been left behind, even after CD45+ cell depletion of
the tumor. These tumors were transferred to K14-TSLPtg Tslpr–/–
female mice, which, prior to tumor implantation, had received
Tslpr–/– or congenically marked WT CD4+ T cells from naive
mice (Figure 6A). Interestingly, the breast tumors that formed in
inguinal mammary fat pads of the recipient K14-TSLPtg Tslpr–/–
mice were significantly smaller in the mice receiving WT CD4+
T cells than in those receiving Tslpr–/– CD4+ T cells (Figure 6B;
P < 0.05, Student’s t test). A similar result was obtained when the
tumor cells were injected into thoracic mammary fat pads (Supplemental Figure 15). Remarkably, the majority of the tumorinfiltrating WT CD4+ T cells that rendered recipient K14-TSLPtg
Tslpr–/– mice resistant to breast tumors became GATA3+ Th2 cells
and showed a higher degree of proliferation compared with the
Tslpr–/– CD4+ T cells present in the tumor (Figure 6C). Collectively,
these data provide strong evidence that Th2 cells stimulated by
TSLP are at the heart of the antitumor immunity against breast
cancer development, while also indicating that the breast tumor
cells themselves are not responding to TSLP.
Topical induction of TSLP blocks breast tumor growth in a Th2
cell–dependent manner. We hypothesized that the induction of
TSLP at the time of breast cancer development provides the potential to be an effective immunotherapeutic approach for breast cancer treatment. To test this hypothesis, we used an FDA-approved
topical medication, calcipotriol, which is a known inducer of TSLP
in the skin (11). We administered 20 nmol calcipotriol or EtOH
carrier onto the ears of age-matched WT and Tslpr–/– female mice
every 3 days, starting immediately before adoptive transfer of congenically marked WT CD4+ T cells and implantation of primary

PyMttg Tslpr–/– breast tumor cells into their right inguinal mammary
fat pad (Figure 7A). Topical application of calcipotriol onto the animals’ ears led to a significant increase in circulating TSLP levels
(Figure 7B, P < 0.05, Student’s t test). WT animals that received
calcipotriol developed significantly smaller tumors compared with
EtOH-treated WT controls (Figure 7, C and D, P < 0.05, Student’s t
test). Interestingly, Tslpr–/– mice treated with EtOH developed significantly larger tumors than did EtOH-treated WT controls (Figure 7, C and D, P < 0.05, Student’s t test). This finding demonstrates
that endogenous TSLP released by the breast cancer cells (Supplemental Figure 16) acts to suppress breast cancer growth (Figure 7, C
and D). Tslpr–/– mice treated with calcipotriol showed tumor growth
kinetics similar to that seen in EtOH-treated Tslpr–/– mice, demonstrating that the calcipotriol effect on breast cancer suppression is
mediated through TSLP (Figure 7, C and D). Importantly, Tslpr–/–
mice that received both WT CD4+ T cells and calcipotriol gained
a robust resistance to breast tumor growth, highlighting the observation that CD4+ T cells directly responded to TSLP signal and
mounted an antitumor immune response in the breast (Figure 7, C
and D, P < 0.05, Student’s t test).
To further investigate the nature of the CD4+ T cells responsible for antitumor immunity in the breast in response to topical
calcipotriol treatment, we determined their transcription factor
expression pattern. As shown in a genetic model of TSLP induction, WT mice treated with calcipotriol showed expansion of
GATA3+ Th2 cells in their growth-arrested tumors (Figure 7E).
Notably, WT CD4+ T cells that were transferred into calcipotrioltreated Tslpr–/– mice and responsible for mounting the TSLPinduced antitumor immune response became GATA3+ Th2 cells
(Figure 7E). Evaluation of ears, back skin, and lungs in the calcipotriol-treated animals showed localized inflammation in the
jci.org   Volume 126   Number 4   April 2016
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Figure 5. T cells are required for TSLP-induced antitumor immunity in the breast. (A) CD4+ and CD8+ T cell depletion starting in the second week of life
abrogated the atopic dermatitis–like skin inflammation in K14-TSLPtg PyMttg mice. Representative images are shown of H&E- and toluidine blue–stained
skin from adult PyMttg and K14-TSLPtg PyMttg mice. The animals were analyzed when the control Ab–treated PyMttg mice had developed terminal disease.
The average number of mast cells in 10 random hpf is shown as a bar graph in the left edge of the images (*P < 0.05 compared with PyMttg treated with
control Ab, Student’s t test). Scale bars: 100 μm. (B–D) K14-TSLPtg PyMttg female mice treated with anti-CD4 and anti-CD8 Abs (CD4/8 Ab) lost their
resistance against breast cancer development. Graphs show (B) the time to tumor onset, (C) the average number of breast tumors per mouse, and (D) the
survival percentage for anti-CD4–, anti-CD8–, and control Ab–treated PyMttg and K14-TSLPtg PyMttg mice (n = 6 in each group). *P < 0.05, log-rank test
(B and D); *P < 0.05 starting at week 12 compared with PyMttg treated with control Ab, Student’s t test (C).

ears, but no sign of systemic allergic inflammation at the barrier
organs in response to the short-term induction of TSLP through
topical calcipotriol treatment (Supplemental Figure 17). Together,
these findings demonstrate the tumor-suppressive effects of
endogenous TSLP expressed by a developing breast cancer and
substantiate the potential of TSLP induction to yield an effective
immunotherapeutic for breast cancer treatment with minimal
systemic side effects.
TSLP induction blocks tumor growth in late-stage breast cancer. We have demonstrated that systemic induction of TSLP
and local TSLP expression by breast cancer cells act to suppress
breast cancer development. In contrast to our findings, previous
studies showed that endogenous TSLP released from breast cancer cell lines is protumorigenic (10, 28). To test the effects of systemic TSLP induction on a breast cancer cell line, we generated
a cell line from PyMttg breast tumors (Supplemental Figure 18A).
Consistent with previous findings (10, 28), WT animals injected
with the PyMttg tumor cell line developed significantly larger
tumors compared with Tslpr–/– recipients (Supplemental Figure
18; P < 0.05, Student’s t test). The reason for the opposite effect of
endogenous TSLP on tumor cell lines is unclear, but it should be
noted that breast cancer cell line–derived tumors are poorly differ1464
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entiated and have lost epithelial characteristics such as cytokeratin
expression, similar to a late-stage metastatic cancer (Supplemental Figure 19). Nonetheless, we found that tumor cell line growth
was still suppressed in K14-TSLPtg animals (Supplemental Figure
18; P < 0.05 compared with WT, Student’s t test). Notably, CD4+ T
cells, which were largely GATA3+ Th2 polarized, constituted the
majority of tumor-infiltrating lymphocytes in K14-TSLPtg mice
compared with WT and Tslpr–/– animals (Supplemental Figure 18;
P < 0.05, Student’s t test). Thus, TSLP expressed locally by breast
tumor cells can be coopted by tumor-derived cell lines to promote
the growth of the breast tumor cells, but TSLP induction can still
block their growth by recruiting Th2 cells to the tumor, consistent with our findings of the tumor-suppressive effect of TSLP on
developing primary tumors.
TSLP induction blocks pancreatic tumor growth. In order to
determine the extent of the TSLP tumor–suppressive effects in
blocking early cancer development, we examined the role of TSLP
in pancreatic cancer, which is a prime example of a cancer with
minimal baseline immunity (3). A previous study has suggested
that endogenous TSLP released by pancreatic cancer–associated
fibroblasts is protumorigenic in metastatic pancreatic cancer (29).
Therefore, elucidating the role of TSLP in early-stage pancreatic
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Figure 6. TSLP blocks breast cancer promotion through
stimulation of Th2 cells. (A) Schematic diagram depicting the
experimental paradigm used to test the role of CD4+ T cells in
TSLP-mediated immunity against breast cancer. Six- to eightweek-old K14-TSLPtg Tslpr–/– animals received WT or Tslpr–/–
CD4+ T cells and were implanted 2 days later with PyMttg
Tslpr–/– primary breast tumors. WT CD4+ T cells were congenically marked (CD45.1+). (B) WT CD4+ T cells were sufficient to
receive TSLP signal and mount an antitumor immune response
in the breast. Representative images are shown of K14-TSLPtg
Tslpr–/– mice with their implanted tumors. Red arrow points
to a small tumor in the K14-TSLPtg Tslpr–/– animal injected
with WT CD4+ T cells. Shown are H&E-stained tumor sections
isolated from K14-TSLPtg Tslpr–/– animals that received WT or
Tslpr–/– CD4+ T cells. Inset highlights an area of the tumor that
shows reversion to a dilated gland structure in a small tumor
that formed in the K14-TSLPtg Tslpr–/– mouse injected with WT
CD4+ T cells. Scatter plot shows the average volume of the
breast tumors forming in each K14-TSLPtg Tslpr–/– mouse that
received WT or Tslpr–/– CD4+ T cells at the time point when the
tumors of the Tslpr–/– T cell–injected animals had reached their
terminal volume (n = 8 in each group; *P < 0.05, Student’s t
test). Scale bars: 1 cm (mouse), 500 μm (histology). (C) WT
CD4+ T cells isolated from growth-arrested breast tumors of
K14-TSLPtg Tslpr–/– mice were polarized to Th2 cells and showed
increased proliferation. Representative flow cytometric plots
show the FOXP3 and GATA3 expression status of tumorinfiltrating CD4+ T cells in K14-TSLPtg Tslpr–/– mice that received
WT or Tslpr–/– CD4+ T cells. Congenically marked (CD45.1+) WT
CD4+ T cells are highlighted in red. Numbers in the flow plots
represent the percentage of cells within each box. Histograms
show the percentage of Ki67+CD4+ T cells.

cancer has major implications for our understanding of TSLP’s
function in cancer. To test the effect of TSLP induction on pancreatic cancer development, we isolated spontaneous pancreatic
tumors from P48+/Cre LSL-KRASG12D p53fl/+ animals (30). These
primary tumors were transferred into WT and K14-TSLPtg mice
to monitor their growth in the presence of systemic TSLP. Interestingly, pancreatic tumors formed in K14-TSLPtg mice were significantly smaller than those formed in WT mice (Figure 8, A and
B; P < 0.05, Student’s t test). Importantly, there was a significant
increase in the number of GATA3+ Th2 cells infiltrating K14-TSLPtg
tumors compared with that seen in their WT counterparts (Figure
8, C and D; P < 0.05, Student’s t test). These findings demonstrate

that systemic TSLP induction against primary pancreatic tumors
leads to their growth suppression, accompanied by a significant
accumulation of Th2 cells within the tumor microenvironment.

Discussion

The main impact of this report is the demonstration that an antitumor immune response can be effectively induced against early
stages of cancer development. The ability to activate the immune
system to attack a developing cancer highlights a novel aspect of
cancer immunology with great potential to produce robust and
durable treatments against cancer. This approach can yield cancer
immunopreventive measures that will eliminate carcinoma in situ,
jci.org   Volume 126   Number 4   April 2016
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Figure 7. Topical TSLP induction blocks
breast cancer development. (A) Schematic diagram outlining the experimental
design used to test the efficacy of topical
calcipotriol treatment in blocking breast
cancer development. Six- to eight-weekold WT and Tslpr–/– animals were used
as tumor recipients. The animals were
treated with 20 nmol calcipotriol or EtOH
on their ears every 3 days, starting before
adoptive T cell transfer (in a subgroup of
Tslpr–/– animals) and PyMttg Tslpr–/– primary breast tumor implantation. (B) Topical calcipotriol treatment on ears led to
elevated TSLP levels in the circulation. Bar
graph shows the average levels of TSLP
in the serum of WT mice treated with
calcipotriol or EtOH (*P < 0.05, Student’s
t test). (C and D) TSLP induction by calcipotriol blocked breast tumor growth in a
TSLP- and CD4+ T cell–dependent manner.
Endogenous TSLP expressed by breast
tumor cells also acted to suppress breast
tumor growth. (C) Graph demonstrates
the average tumor volumes in 5 cohorts of
mice tested (n = 6 in each group; *P < 0.05
compared with the WT plus EtOH group,
Student’s t test). (D) Representative
images of the implanted primary breast
tumors are shown (red arrow points to
small tumors). Scale bar: 1 cm. (E) CD4+
T cells in calcipotriol-treated WT mice and
WT CD4+ T cells transferred into calcipotriol-treated Tslpr–/– mice were polarized to
Th2 cells. Representative flow cytometric
plots of tumor-infiltrating CD4+ T cells
in recipient mice are shown (numbers in
each box represent the percentage of CD4+
T cells). Congenically marked (CD45.1+)
WT CD4+ T cells are highlighted in red.
Bar graph shows the percentage of Th1
and Th2 cells and Tregs within the breast
tumors in each group (n = 6 per group;
*P < 0.05 compared with the WT plus
EtOH group, Student’s t test). The data
were reproduced in 3 independent
experiments.
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Figure 8. TSLP suppresses primary pancreatic
tumor growth. (A) Graph shows the average volume
of P48+/Cre LSL-KRASG12D p53fl/+ pancreatic tumors
transferred into WT and K14-TSLPtg mice over time.
(B) Representative images show tumors 30 days
after implantation of primary pancreatic tumor
cells into the right flank of 6- to 8-week-old WT and
K14-TSLPtg mice. Scale bar: 1 cm. (C) Bar graph shows
the percentage of T-bet+ Th1 cells, GATA3+ Th2 cells,
and FOXP3+ Tregs in the pancreatic tumors formed
in WT and K14-TSLPtg animals. (D) Representative
flow cytometric plots demonstrate FOXP3, GATA3,
and T-bet expression in tumor-infiltrating CD4+ T
cells in recipient mice. The data were reproduced in 2
independent experiments (n = 6 in each group;
*P < 0.05 compared with WT, Student’s t test).
Detailed experimental procedures are available in the
Supplemental material.

prevent the development of late-stage metastatic cancers, and
result in the recruitment of a much broader repertoire of immune
effector cells against early and late cancers.
Here, we demonstrate that TSLP-stimulated CD4+ Th2 cells
are the key mediators of the antitumor immune response that
blocks early stages of breast cancer development, protecting animals from advanced breast cancer and metastasis. Importantly,
we found that a similar TSLP-induced immunity blocked the
growth of primary pancreatic tumors. These findings identify several fundamental concepts that can advance our understanding of
immune system interactions with cancer. First, our data suggest
that, in addition to CD8+ CTLs, which are the prime immune cell
type studied in cancer immunology (1), CD4+ Th cells are important players in antitumor immunity, especially in early cancers.
This finding suggests that CD8+ CTLs found in late-stage cancers
may have been initially recruited by CD4+ Th cells responding to
the cancer at its earlier stages of development, similar to the initiating role that CD4+ T cells play in other inflammatory conditions like autoimmune diabetes (31). Next, this work emphasizes
the importance of actively stimulating CD4+ Th cells against early
stages of solid cancers like breast cancer, in which baseline antitumor immunity is minimal (3). Through this approach, tumorinfiltrating CD4+ T cells, which are the upstream activators of the
immune response, can mediate potent anticancer effects. The
CD4+ T cells appeared not to be cytotoxic themselves and did not
express tumor-promoting factors; rather, they recruited a broad
repertoire of immune effector cells to attack the cancer more
effectively. However, the observed effects appear to be independent of mast cells or basophils, since they were found in low densities and were not expanded upon TSLP exposure in the breast
cancer lesions. Thus, Th2-polarized lymphocytes are at the heart

of the antitumor immune response in the breast, which signifies
the previously unrecognized efficacy of this immune cell type in
suppressing cancer development.
Although the tumor-protective effects of atopy against skin
cancer have been previously described (7–9, 32), this study provides clear evidence for a similar effect against an internal cancer
with metastatic potential. TSLP is a master regulator of atopic diseases in barrier organs like the skin and lungs (33). In response to
barrier disruption, TSLP is expressed by epithelial cells that are
attempting to repair the barrier and alert the immune system of
the breach. However, in the face of chronic barrier defects, continuous TSLP overexpression leads to the development of atopic
dermatitis and asthma in the skin and lungs, respectively (33). Previous reports demonstrated that TSLP-induced allergic inflammation in the skin protected it from cancer (7–9); however, it was not
clear whether this protection would extend to cancers in nonbarrier sites. We believe our current findings conclusively demonstrate that systemic TSLP released by the skin mounts an effective
antitumor immune response specifically at the site of a developing
cancer in the breast and does not cause inflammation in a breast
free of initiated cancer cells. Therefore, a barrier organ site for the
tumor and preexisting allergic inflammation are not required for
TSLP-mediated tumor immunity.
As TSLP is increased in the blood of patients with atopic diseases (18), our results provide an explanation for the reduced rate
of cancer in these patients reported in epidemiological studies
(15–17). In addition, our calcipotriol studies demonstrate that a
short-term induction of systemic TSLP leads to antitumor immunity at the sites of breast cancer development, without generalized allergic inflammation as side effects. Hence, the systemic
approach to TSLP induction may provide a safe and effective
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immunotherapy to direct the antitumor immunity specifically to
the site of the primary cancer and its micrometastasis.
Importantly, we found that in breast cancer–derived cell lines,
the endogenous TSLP signal is coopted by the cancer cells to promote their growth, as shown in previous studies (10, 28). This protumorigenic effect of TSLP on breast cancer cell lines is mediated
through OX40L+ DCs (10) and may involve a collection of immune
cells like the M2 macrophages present in a type 2 inflammatory
microenvironment (34). Interestingly, systemic TSLP overexpression can still stimulate the specific expansion of CD4+ T cells in the
cell line–derived breast tumor and block its growth. Collectively,
these results emphasize the importance of TSLP as a potent antitumor immune signal that can be deployed to achieve an effective
immunity against early- and late-stage breast cancer.
An important and direct implication of TSLP induction for
breast cancer immunotherapy relates to the treatment of lobular
and ductal carcinoma in situ (LCIS and DCIS). These localized
breast lesions have high rates of recurrence, even after surgical
excision (35, 36). More important, the presence of a subset of
these precancerous lesions is a marker for increased risk of cancer
in both breasts (35, 36). Importantly and consistent with our findings in animal models, a clinical study recently found that TSLP
expression in early-stage breast cancers correlates with improved
outcomes (37). Therefore, TSLP induction can prove to be an
effective cancer immunotherapeutic against these early breast
cancer lesions by directing the adaptive immunity to sites of existing but subclinical cancers and preventing new lesions from developing over time through the immune memory response.
TSLP establishes its tumor immunity against breast cancer
by stimulating CD4+ T cells to infiltrate the breast cancer as activated and/or memory Th2 cells. Although we have shown that
TSLP-stimulated CD4+ T cells accumulate in close proximity to
MHCII+ APCs that have also infiltrated the tumor under TSLP
pressure, the exact nature of the antigens that are detected by
these T cells remains to be elucidated in future studies. Also, the
effector mechanism of the TSLP-stimulated Th2 cells that effectively blocks breast cancer development remains a topic for future
research. We did not find that the tumor-infiltrating CD4+ T cells
express granzymes, perforin, or Fas ligand, which would give rise
to cytotoxic potential. Therefore, other adaptive immune cells
like B cells (32) and CD8+ CTLs, as well as innate immune cells
and/or stromal components of the tumor, are likely playing an
effector role downstream of the CD4+ T cells to execute the antitumor effects observed.
In summary, this work describes previously unrecognized
effects of TSLP and Th2 cells in blocking breast carcinogenesis
that can be extended to other cancers, such as pancreatic cancer.
TSLP overexpression in the skin establishes a potent antitumor
immunity in the breast through direct stimulation of CD4+ Th2
cells. Likewise, endogenous TSLP released by breast cancer cells
suppresses the growth of the cancer, which is later used by breast
cancer–derived cell lines to promote their own growth. Together,
these findings demonstrate the importance of studying cancer
immunology in the context of a developing spontaneous cancer in
order to determine the full breadth of immune system interactions
with cancer. This study has clear therapeutic implications for the
treatment of early and late cancers by providing a mechanism to
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engage the CD4+ T cells to attack the cancer. More specifically, the
efficacy of topical calcipotriol in inhibiting breast cancer growth in
a TSLP- and Th2 cell–dependent manner provides an exciting possibility for the use of this FDA-approved medication in the treatment of early breast cancer lesions, especially those that are not
cured by surgical excision alone.

Methods

Mice. Mice carrying both K14-TSLPtg (a gift of Andrew Farr, University of Washington, Seattle, Washington, USA) and PyMttg transgenes
were generated by crossing PyMttg mice on an FVB background with
K14-TSLPtg mice on a mixed background. These K14-TSLPtg PyMttg
mice were maintained on an FVB background. For experiments using
mice on the C57BL/6 background, PyMttg mice generated directly
on a C57BL/6 background were crossed with K14-TSLPtg Tslpr–/– mice
(Tslpr–/– mice were a gift of Warren Leonard, NIH, Bethesda, Maryland,
USA) that were also generated directly on a C57BL/6 background. All
mice included in the breast cancer experiments were monitored daily
for tumor onset and growth. For all breast cancer experiments, the mice
were sacrificed if their tumor exceeded 2 cm in diameter or the animals
showed any sign of distress or weight loss. In cancer survival experiments, we harvested one K14-TSLPtg PyMttg animal, together with any
of its end-stage cancer–bearing PyMttg littermates, in order to perform
our tissue and immune cell analyses on the test and control mice at the
same age; hence, some of the K14-TSLPtg PyMttg animals that were otherwise healthy exited the survival analysis at the time of euthanasia.
Ab depletion. K14-TSLPtg PyMttg and PyMttg mice received an i.p.
injection of 750 μg anti-CD4 (GK1.5) and/or anti-CD8 (YTS169.4) or
control Ab (anti-rat IgG; Sigma-Aldrich) in the second week of life.
The animals continued to receive 250 μg depleting Abs weekly. AntiCD4 and anti-CD8 Abs were produced by the Protein Production and
Purification Facility of the Rheumatic Diseases Core Center (RDCC)
at Washington University.
Primary breast tumor transfer and calcipotriol treatment studies. Primary breast tumor cells were obtained from PyMttg or PyMttg Tslpr–/–
donor mice. Primary tumors in the donor animals were harvested
before the tumors reached 2 cm in diameter. Donor mice were injected
with 50 μl heparin, followed by anesthetics and whole-body perfusion
with 30 ml PBS under sterile conditions. Approximately 3 to 4 grams
of whole tumor was then meshed through a 70-μm filter into a lysing
solution consisting of RPMI (Sigma-Aldrich), Liberase TL (170 μg/
ml; Roche), and DNase I (30 μg/ml; Roche) in a 6-well plate. A breast
tumor single-cell suspension and small pieces were transferred into a
50-ml tube and placed in a shaker at 37°C for 2 hours at 225 rpm. A
breast tumor single-cell suspension was then meshed through a new
70-μm filter into a fresh 50-ml tube. Breast tumor cells were resuspended in 2 ml MACS buffer (0.5% BSA and 2 mM EDTA in PBS), followed by 100 μl CD45+ microbeads for 30 minutes on ice (Miltenyi
Biotec). Primary breast tumor cells were isolated away from CD45+
leukocytes using CD45+ microbeads and magnetic columns according
to the manufacturer’s protocol (Miltenyi Biotec). Primary breast tumor
cells were resuspended at a concentration of 2 × 106 cells per 200 μl
RPMI (Sigma-Aldrich). Cells (2 × 106/mouse) were injected into the
animals’ right inguinal mammary fat pad (ninth mammary gland) on
day 0 (D0). For adoptive T cell transfer experiments, CD4+ T cells
were injected 2 days before tumor implantation. In topical calcipotriol
treatment experiments, the mice were divided into 2 groups and were
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treated with either calcipotriol (20 nmol) or ethanol as a carrier on
their ears starting 2 days before CD4+ T cell transfer. Calcipotriol or
ethanol treatments were continued every 3 days.
Breast cancer cell line studies. The PyMttg cancer cell line was generated from a mammary tumor from a 6-month-old PyMttg mouse on
a C57BL/6 background. Tumor cells were grown on collagen-coated
plates in 10% FBS plus DMEM and passaged 10 times before use. The
cell line was screened for vimentin and EpCAM to verify its epithelial nature. Cells were screened for mouse Ab production (MAP) and
mycoplasma. Cells were passaged at 70% confluency, and 4 × 105
breast cancer cells were injected into the lateral inguinal mammary fat
pad (ninth mammary gland) on D0.
Statistics. All statistical analyses for tumor onset and survival were
performed using the log-rank test to determine significant differences
between study groups in 2-way comparisons with the control group. A
2-tailed Student’s t test was used to determine significance between
tumor counts, tumor volumes, mRNA expression, TSLP serum levels,
and all other measurements in 2-way comparisons with the control
group. A P value of less than 0.05 was considered significant, and all
error bars represent SD.
Study approval. All mice were maintained in pathogen-free facilities according to guidelines instituted by the animal study committees
of Washington University and Massachusetts General Hospital. All
animal studies were reviewed and approved by the IACUCs of Washington University and Massachusetts General Hospital.
Refer to the Supplemental Methods for further description of the
experimental procedures.
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